Analysts Expect Intec Pharma Ltd. (NTEC) Will Post Earnings of -$0.28 Per Share

Brokerages expect Intec Pharma Ltd. (NASDAQ:NTEC) to post earnings of ($0.28) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Intec Pharma’s earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.29). The firm is scheduled to issue its next quarterly earnings results on Friday, June 8th.

On average, analysts expect that Intec Pharma will report full year earnings of ($1.02) per share for the current financial year, with EPS estimates ranging from ($1.22) to ($0.86). For the next fiscal year, analysts forecast that the business will post earnings of ($0.79) per share, with EPS estimates ranging from ($1.25) to ($0.50). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Intec Pharma.

Intec Pharma (NASDAQ:NTEC) last announced its quarterly earnings results on Friday, March 9th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.19).

NTEC has been the topic of a number of research reports. HC Wainwright set a $16.00 target price on shares of Intec Pharma and gave the stock a “buy” rating in a report on Sunday, March 18th. Ladenburg Thalmann initiated coverage on shares of Intec Pharma in a report on Wednesday, February 28th. They set a “buy” rating on the stock. Maxim Group boosted their target price on shares of Intec Pharma from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, March 26th. Oppenheimer set a $15.00 target price on shares of Intec Pharma and gave the stock a “buy” rating in a report on Tuesday, March 13th. Finally, Zacks Investment Research lowered shares of Intec Pharma from a “hold” rating to a “sell” rating in a report on Friday, March 16th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $12.67.

Several large investors have recently bought and sold shares of NTEC. Meitav Dash Investments Ltd. acquired a new position in shares of Intec Pharma during the 4th quarter valued at $8,607,000. Renaissance Technologies LLC lifted its position in shares of Intec Pharma by 66.0% during the 4th quarter. Renaissance Technologies LLC now owns 133,500 shares of the biotechnology company’s stock valued at $688,000 after acquiring an additional 53,100 shares during the period. Millennium Management LLC acquired a new position in shares of Intec Pharma during the 4th quarter valued at $1,392,000. JPMorgan Chase & Co. acquired a new position in shares of Intec Pharma during the 1st quarter valued at $138,000. Finally, Deutsche Bank AG lifted its position in shares of Intec Pharma by 59.2% during the 4th quarter. Deutsche Bank AG now owns 115,217 shares of the biotechnology company’s stock valued at $593,000 after acquiring an additional 42,867 shares during the period. 32.84% of the stock is currently owned by institutional investors.

Shares of Intec Pharma traded up $0.05, hitting $4.95, during midday trading on Wednesday, MarketBeat Ratings reports. 600 shares of the company traded hands, compared to its average volume of 183,840. Intec Pharma has a 12 month low of $4.95 and a 12 month high of $4.95.

Intec Pharma Company Profile

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply